Although with variable rates, discordances in the biomarker profile between PTs and ALNs have emerged, such as hormone-sensitive tumors with negative metastases [10,11] or HER2-negative breast neoplasms with overexpression/FISH amplification in lymph nodes [13,14], among others. This evidence concerns the gene ERBB2 and breast neoplasm.